A secondary RET mutation in the activation loop conferring resistance to vandetanib
Mechanisms of acquired resistance to RET tyrosine kinase inhibitors in lung cancers are largely unknown. Here, the authors report in a lung adenocarcinoma patient harboring a CCDC6-RET mutation in the RET kinase (S904F) that results in resistance to the kinase inhibitor vandetanib by increasing the...
Full description
Bibliographic Details
Main Authors: |
Takashi Nakaoku,
Takashi Kohno,
Mitsugu Araki,
Seiji Niho,
Rakhee Chauhan,
Phillip P. Knowles,
Katsuya Tsuchihara,
Shingo Matsumoto,
Yoko Shimada,
Sachiyo Mimaki,
Genichiro Ishii,
Hitoshi Ichikawa,
Satoru Nagatoishi,
Kouhei Tsumoto,
Yasushi Okuno,
Kiyotaka Yoh,
Neil Q. McDonald,
Koichi Goto |
Format: | Article
|
Language: | English |
Published: |
Nature Publishing Group
2018-02-01
|
Series: | Nature Communications
|
Online Access: | https://doi.org/10.1038/s41467-018-02994-7
|